BSE Live
Mar 24, 09:36Prev. Close
4551.85
Open Price
4635.20
Bid Price (Qty.)
4603.30 (1)
Offer Price (Qty.)
4619.55 (2)
NSE Live
Mar 24, 09:36Prev. Close
4560.00
Open Price
4626.00
Bid Price (Qty.)
4610.50 (1)
Offer Price (Qty.)
4612.00 (6)
| Profit & Loss account of Pfizer (in Rs. Cr.) | Nov 09 | Nov 08 | Nov 07 | Nov 06 | Nov 05 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 870.60 | 786.74 | 794.27 | 791.98 | 724.15 | |
| Less: Excise/Sevice Tax/Other Levies | 39.56 | 57.72 | 62.97 | 63.02 | 63.27 | |
| Revenue From Operations [Net] | 831.04 | 729.02 | 731.31 | 728.96 | 660.89 | |
| Total Operating Revenues | 831.04 | 729.02 | 731.31 | 728.96 | 660.89 | |
| Other Income | 70.63 | 66.02 | 319.83 | 33.40 | 11.06 | |
| Total Revenue | 901.68 | 795.03 | 1,051.14 | 762.36 | 671.94 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 209.01 | 196.35 | 149.36 | 138.95 | 154.17 | |
| Purchase Of Stock-In Trade | 79.12 | 72.90 | 87.08 | 104.28 | 94.42 | |
| Operating And Direct Expenses | 33.08 | 30.99 | 29.05 | 29.90 | 29.83 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 9.92 | -22.97 | 4.69 | -10.27 | -34.09 | |
| Employee Benefit Expenses | 134.80 | 105.14 | 119.05 | 125.71 | 123.51 | |
| Finance Costs | 0.00 | 0.00 | 0.02 | 0.07 | 0.16 | |
| Depreciation And Amortisation Expenses | 8.29 | 11.12 | 9.58 | 13.07 | 13.85 | |
| Other Expenses | 220.10 | 198.20 | 203.78 | 198.64 | 180.86 | |
| Total Expenses | 694.31 | 591.73 | 602.61 | 600.35 | 562.70 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 207.36 | 203.31 | 448.53 | 162.01 | 109.24 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 207.36 | 203.31 | 448.53 | 162.01 | 109.24 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 77.05 | 124.51 | 107.40 | 58.54 | 43.80 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -4.83 | -7.35 | 1.38 | -5.33 | -2.68 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 73.13 | 119.44 | 111.20 | 56.28 | 41.13 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 134.23 | 83.86 | 337.33 | 105.73 | 68.12 | |
| Profit/Loss From Continuing Operations | 136.88 | 299.12 | 338.93 | 105.73 | 67.83 | |
| Profit/Loss For The Period | 136.88 | 299.12 | 338.93 | 105.73 | 67.83 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 45.87 | 100.23 | 113.57 | 35.43 | 22.73 | |
| Diluted EPS (Rs.) | 45.87 | 100.23 | 113.57 | 35.43 | 22.73 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 58.74 | 44.01 | 32.97 | 22.92 | 9.37 | |
| Indigenous Raw Materials | 85.69 | 95.83 | 62.59 | 64.24 | 92.28 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 37.30 | 37.30 | 82.06 | 37.30 | 29.84 | |
| Tax On Dividend | 6.34 | 6.34 | 13.95 | 5.23 | 4.19 | |
| Equity Dividend Rate (%) | 125.00 | 125.00 | 275.00 | 125.00 | 100.00 |
10.02.2026
Pfizer Standalone December 2025 Net Sales at Rs 645.03 crore, up 19.9% Y-o-Y
13.11.2025
Pfizer Standalone September 2025 Net Sales at Rs 642.34 crore, up 9.13% Y-o-Y
20.05.2025
Pfizer Standalone March 2025 Net Sales at Rs 591.91 crore, up 8.28% Y-o-Y
01.02.2025
Pfizer Standalone December 2024 Net Sales at Rs 537.99 crore, down 0.37% Y-o-Y
19.10.2016
05.08.2016
03.01.2014
10.01.2011
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth